Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · iBio, Inc. (IBIO)

iBio Highlights Monkey Data: IBIO-610 Plus Semaglutide Weight Loss Mostly Fat

Neutral Impact 3 of 5 other Written later

iBio presented preclinical data from an eight-week obese non-human primate study of IBIO-610, a potential first-in-class Activin E antibody, at the EASD Annual Meeting on October 1, 2026. The company reported that fat made up 93% of weight lost with IBIO-610 plus semaglutide, versus 77% with semaglutide alone, and it plans to begin first-in-human studies in the first half of 2027. The data are early animal results, and the filing notes they may not be replicated in humans.

Key points

  • Lean mass was 6% of weight lost with IBIO-610 plus semaglutide, versus 22% with semaglutide alone (eight-week study, n=6 per group)
  • At week 8, fat accounted for 93% of weight lost with IBIO-610 plus semaglutide, versus 77% with semaglutide alone
  • IBIO-610 reduced serum levels of active Activin E by 97% at week 8 after a single intravenous dose, and had a 33.2-day half-life in NHPs
  • First-in-human studies are planned to begin in the first half of 2027

The filing

CompanyiBio, Inc. (IBIO)
Form8-K, current report
Filed with the SECOct 13, 2026, 8:25 AM ET
Accession number0001420720-26-000030

Items reported: 7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 13, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.